Guggenheim Maintains Buy on Relay Therapeutics, Raises Price Target to $26

Benzinga Newsdesk www.benzinga.com Positive 75.2%

Neg 0% Neu 0% Pos 75.2%

Guggenheim analyst Brad Canino maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $22 to $26.